APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

NCT04858334 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

152

Enrollment

NIH

Sponsor class

Conditions

Pancreatic Acinar Cell Carcinoma
Pancreatic Adenosquamous Carcinoma
Pancreatic Squamous Cell Carcinoma
Resectable Pancreatic Acinar Cell Carcinoma
Resectable Pancreatic Adenocarcinoma
Resectable Pancreatic Adenosquamous Carcinoma
Resectable Pancreatic Carcinoma

Interventions

PROCEDURE: Biospecimen Collection
PROCEDURE: Computed Tomography
PROCEDURE: Magnetic Resonance Imaging
DRUG: Olaparib
DRUG: Placebo Administration

Sponsor

National Cancer Institute (NCI)